MDXG 10.40 Mimedx Group Inc $MDXG Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 1:31 PM

MDXG 10.40 Mimedx Group Inc $MDXG Hit a 52 week high of 10.50 Closing the day 09:44 at 10.40 -0.04 -0.38% With a day low of 10.35 and a total volume of 8,685.

MDXG Recent Posts: http://investorshangout.com/MiMedx-Group-Inc-MDXG-64149/

MDXG Mimedx Group Inc Recent Headline News

MiMedx elects Christopher M. Cashman as EVP
M2 - Mon Nov 10, 8:11AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) announced on Friday that it has appointed Christopher M. Cashman as its executive vice president & chief commercialisation officer.
MDXG: 10.39 (-0.05)

MiMedx® Adds New Executive
PR Newswire - Fri Nov 07, 8:39AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer.
MDXG: 10.39 (-0.05)

Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.01 (-0.06), OPK: 8.27 (-0.07), VNDA: 11.93 (-0.24), MDXG: 10.39 (-0.05), PDLI: 7.75 (-0.14)

MiMedx To Present At Two Healthcare Conferences
PR Newswire - Wed Nov 05, 1:59PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at two healthcare conferences in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present at the 2014 Stifel Healthcare Conference on Wednesday, November 19, 2014 at 11:30 am EST at the Palace Hotel. Management will also present at 8:00 am EST on Thursday, November 20, 2014, at the Canaccord|Genuity Forum, which is being held at the Westin Grand Central Hotel. Webcasts of each presentation will be available on the Company's website, www.mimedx.com.
MDXG: 10.39 (-0.05)

MiMedx raises full year 2014 guidance after Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 5:42AM CDT

MDXG: 10.39 (-0.05)

MiMedx Group's (MDXG) CEO Parker Petit on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 4:54PM CDT

MDXG: 10.39 (-0.05)

MiMedx Group beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:11AM CDT

MDXG: 10.39 (-0.05)

MiMedx Achieves Record Revenue And Records First Operating Profit
PR Newswire - Thu Oct 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its results for the third quarter ended September 30, 2014.
MDXG: 10.39 (-0.05)

Despite the Downtrend, This Strong Buy Stock is Outperforming - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 23, 1:23PM CDT
This top ranked stock has been a winner as of late, and given strong momentum, it could continue to soar.
MDXG: 10.39 (-0.05)

MiMedx Provides Update On Outstanding Patent Litigation
PR Newswire - Tue Oct 21, 11:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations.
MDXG: 10.39 (-0.05)

Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
MiMedx Group could be a great candidate for another beat after a solid performance in the last two quarters
MDXG: 10.39 (-0.05)

Surging Earnings Estimates Signal Good News for MiMedx Group (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:46AM CDT
MiMedx Group has decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
MDXG: 10.39 (-0.05)

MiMedx (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
MiMedx (MDXG) Shares March Higher, Can It Continue?
MDXG: 10.39 (-0.05)

MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
PR Newswire - Thu Oct 16, 9:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.
MDXG: 10.39 (-0.05)

MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 8.35 (-0.04), MYGN: 32.85 (-0.50), HALO: 8.48 (-0.26), MDXG: 10.39 (-0.05)

MiMedx Group's (MDXG) CEO Pete Petit Hosts Analyst Day (Transcript)
SA Transcripts - at Seeking Alpha - Tue Oct 14, 7:13PM CDT

MDXG: 10.39 (-0.05)

MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
PR Newswire - Mon Oct 13, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance.
MDXG: 10.39 (-0.05)

MiMedx Announces Release Date for 2014 Third Quarter Results
PR Newswire - Mon Oct 06, 3:29PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, October 30, 2014. MiMedx will host a live broadcast of its third quarter conference call on Thursday, October 30, 2014, at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 10.39 (-0.05)

MiMedx to Present at the Stem Cell Meeting on the Mesa
PR Newswire - Tue Sep 30, 3:08PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
MDXG: 10.39 (-0.05)

MiMedx Signs Distribution Agreement With Zimmer
PR Newswire - Thu Sep 18, 8:29AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM"

allograft products to Zimmer to be marketed non- exclusively on a private label basis.
MDXG: 10.39 (-0.05)

MiMedx Group Inc (MDXG) Stock Research Links

MDXG Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's Long March: Legacy Shaping a New Era

The Enduring Spirit of the Long March Remember the original Long March? Two years, 25,000 li, and countless struggles. It was more than a military campaign—it was a flame of hope burning in the bleakest of times. Even today, folks in China still nod to its spirit as they navigate the nation's economic and social landscape. You might ask, "Why hold onto an event from 90...

Watchtower Labs: New Era of AI in Military Ops

Big Moves in Military Planning Alright, folks, here's the skinny on something that's bound to shake up the military sector: Watchtower Labs has kicked the door open after its stealthy beginnings with a hefty $35 million in seed funding. Investors like Shield Capital, Conviction, and Founders Fund are throwing their weight behind this AI-powered venture that's poised to...

Trimble's AI Boosts Construction Risk Management

Navigating Construction's Risky Waters La-di-da, another day, another dollar lost—or won—in the construction zone. But hey, here comes Trimble waving a shiny new AI-driven flag that promises to shut down those wrench-tossing surprises in construction projects. They're calling it the Document Crunch, a tool that lets contractors review everything from drawings to...

Cystic Fibrosis Market: Emerging Therapies Boost Growth

The landscape of cystic fibrosis treatment is on the cusp of a seismic shift, promising new therapies poised to redefine patient care and market dynamics. As we stand at the intersection of innovation and opportunity, the impending transformation is fueled by groundbreaking therapies, increased healthcare spending, and a stronger push for personalized medicine. The Winds...

Trilogy Metals Advances Arctic Project's Potential

Trilogy Metals Completes Ambler Metals Field Work Alright, folks, let's dive into a mining story that should catch the discerning eye. Trilogy Metals (NYSE: TMQ) proudly wrapped up its 2026 field season at the Upper Kobuk Mineral Projects (UKMP), located in northwestern Alaska. And if you're neck-deep in the mining sector, this isn't just a thing on the periphery; it's a...

How Track Rabbit Levels the Playing Field for Small Motorsport Ventures

Fielding Opportunities in a Revved-Up Market You're knee-deep in grease and exhaust, keeping your motorsport enterprise alive against the big dogs without losing grip on the little guy's budget. What if I told you there's a service out there talking your language – combining marketing prowess with AI smarts for as low as $350 a month? That's ALIVE and Track Rabbit...

ILS and Anduin Join Forces to Streamline Fundraising

Big Moves in Legal Tech and Fundraising In the world of investing, where technology is always a step ahead, Intelligent Legal Solutions (ILS) and Anduin are cooking up a storm with their latest partnership announcement. Targeting private markets fund managers and law firms, these two tech players aim to ease the layered chaos that comes with fundraising by integrating...

Cognizant Buys DyFlex for SAP, AI Edge in ANZ

Why Cognizant's Move Matters Imagine being at the top of your game, only to realize you need more heavy-hitters to keep your edge. That’s this deal in a nutshell. Cognizant (NASDAQ: CTSH) is diving deep into AI-led enterprise transformation by scooping up DyFlex Solutions, a name with plenty of clout in the SAP ecosystem. What's Behind the DyFlex Acquisition? Founded in...

Vermilion Energy Sets Dates for Earnings and Calls

The Anticipation Around Vermilion's Upcoming Results There's a buzz in the air about Vermilion Energy Inc.'s upcoming Q3 2026 financial results. Slated to hit the wires November 4th, before the sun rises on Wall Street, folks in the trade have their eyes peeled to parse through any morsels of data. The question on everyone's mind? Whether they're making the right moves to...

Innventure Investors Alert: Securities Investigation Looms

Innventure's Murky Waters Just when you think you've seen it all, stuff like this reminds you nothing's safe in the market. The law folks at Stranch, Jennings & Garvey, PLLC are sniffing around Innventure, Inc. (NASDAQ: INV) like bloodhounds to see if there's been some hoodwinking going on. We're talking questions about funny business with a data center deal between...